SCHEMBL14227331

SCHEMBL14227331

Cc1ccc(C(=O)Nc2cc(O)ccc2C(=O)O)cc1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.67
KMT2A Q03164 10/20 0.67
MAPT P10636 4/20 0.67
TDP1 Q9NUW8 4/20 0.67
LMNA P02545 1/20 0.67
RAB9A P51151 1/20 0.67
ALDH1A1 P00352 4/20 0.58
HTT P42858 1/20 0.58
PKM P14618 2/20 0.52
GFER P55789 1/20 0.51
AKR1C4 P17516 3/20 0.48
AKR1C3 P42330 3/20 0.48
AKR1C2 P52895 3/20 0.48
AKR1C1 Q04828 3/20 0.48
ABL1 P00519 2/20 0.48
RIN1 Q13671 2/20 0.48
TSHR P16473 1/20 0.48
CHEK1 O14757 1/20 0.47
PIM1 P11309 1/20 0.47
MAPK8 P45983 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14227329 0.90 MEN1 (0.82) MEN1KMT2AMAPTTDP1LMNA
SCHEMBL14227330 0.89 KMT2A (0.67) MEN1KMT2AMAPTTDP1LMNA
SCHEMBL14227314 0.87 MEN1 (0.70) MEN1KMT2AMAPTTDP1LMNA
SCHEMBL9973845 0.87 TOP1 (0.59) MEN1KMT2AMAPTTDP1LMNA
SCHEMBL4669087 0.84 MEN1 (0.65) MEN1KMT2AMAPTTDP1LMNA
SCHEMBL6095280 0.83 CHEK1 (0.63) MEN1KMT2AMAPTTDP1LMNA
SCHEMBL9973843 0.82 TOP1 (0.58) MEN1KMT2AMAPTTDP1LMNA
SCHEMBL6092606 0.80 CHEK1 (0.63) MEN1KMT2AMAPTTDP1LMNA
SCHEMBL6092491 0.80 AKR1C4 (0.68) MEN1KMT2AMAPTTDP1LMNA
SCHEMBL637477 0.79 KMT2A (0.70) MEN1KMT2AMAPTTDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE SYMRISE AG (DE) 2023-04-27 US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 US disclosed
US-20120315233-A1 ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS SYMRISE AG (DE) 2012-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE HPD, CYP4A22, PAH MEN1 2409/4885KMT2A 2584/4885MAPT 1788/4885
US-20120315233-A1 ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS CMA1, TPSAB1, HRH1 MEN1 1612/4885KMT2A 1414/4885MAPT 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.